- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00755703
Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.
A Phase I, Dose-Ranging Safety and Immunogenicity Study of an Adenovirus-vectored Intranasal, Pandemic (Hemagglutinin H5) Influenza Vaccine, ADhVN1203/04.H5, in Healthy Adults
The purpose of this study is to test the recombinant vaccine for safety and immunogenicity in healthy adults volunteers. Single dose, intranasally administered vaccine using an adenovirus-recombinant vector has provided a safe route for inducing protection in animals against pandemic influenza in preclinical studies.
The vaccine is non-replicating, tissue culture based and designed for intranasal delivery.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objectives:
The primary objective is to evaluate the safety of the AdhVN1203/04.H5 vaccine when administered intranasally in two doses with an interval of 28 days in healthy adults 19-49 years of age.
The secondary objective is to evaluated the immunogenicity of the AdhVN1203/04.H5 vaccine at three different doses (10e8, 10e9 and 10e10 viral particles) when administered intranasally in two doses with an interval of 28 days in healthy adults 19-49 years of age.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294-2050
- Alabama Vaccine Research Center (UAB)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy males and females in good general health, 19-49 years of age
- Subjects must provide written consent
- Willing to participate through study completion
- Willing to undergo nasal washes and swabs and provide urine and blood samples per protocol for safety and immunogenicity analysis
- Female of child-bearing age must have a negative urine pregnancy test and be stable on a reliable means of contraception.
- Meet screening criteria for hematology, chemistry and urinalysis
Exclusion Criteria:
- Pregnant (or possibly pregnant) and lactating women
- Any flu/cold symptoms and/or fever greater than 101 degrees in 3 days prior to study enrollment
- Any intranasal steroid medication administered in the 10 days prior to study enrollment
- History of chronic rhinitis or presence of pre-existing nasal septal defects, nasal polyps or other gross abnormalities
- Any previous nasal cautery or significant surgery for nasal septal defects
- Any regular past or current use of intranasal illicit drugs or history of intravenous illicit drug use
- Asthma that is greater than mild in severity
- Diagnosed active Hepatitis B or C
- HIV positive at screening
- Known or suspected malignancy, leukemia, or lymphoma
- Immunosuppressed, altered or compromised immune status as a consequence of disease or treatment with systemic corticosteroids
- Receipt of an influenza vaccine within the past 6 months
- Receipt of any vaccine in the past 30 days
- Receipt of any investigational drug in the past 30 days
- Known Diabetes mellitus
- History of anaphylaxis or angioedema
- Hypertension that is not well controlled
- Any medical, psychiatric, or social condition, or occupational or other responsibility that, in the judgment of the investigator would serve to interfere or serve as a contraindication to, protocol adherence, assessment of safety or reactogenicity, or a participants's ability to give informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
There will be 12 subjects in Group 1 that will receive 10e8 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
|
Undetermined
|
Experimental: Group 2
There will be 12 subjects in Group 2 that will receive 10e9 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
|
Undetermined
|
Experimental: Group 3
There will be 12 subjects in Group 3 that will receive 10e10 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
|
Undetermined
|
Placebo Comparator: Experimental: Group 4
There will be 12 subjects in Group 4 that will receive a placebo consisting of buffer administered via intranasal spray on day 0 and day 28 (+/- 4d).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the safety of a nasally administered adenovirus-vectored pandemic influenza vaccine in healthy human adults.
Time Frame: 56 day observations with 2 year follow-up
|
56 day observations with 2 year follow-up
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determination of immunogenicity and correlates of protection based on HI titers in vaccinates
Time Frame: 28 days and 56 days post vaccination
|
28 days and 56 days post vaccination
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Scott D. Parker, M.D., Alabama Vaccine Research Clinic, University of Alabama at Birmingham
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-0701-2
- #1-UCI-AI-06205-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza A Subtype H5N1 Infection
-
IDRIDefense Advanced Research Projects Agency; MedicagoCompletedInfluenza A Subtype H5N1 InfectionUnited States
-
Institute of Vaccines and Medical Biologicals,...Department of Health and Human Services; Institut Pasteur; PATH; World Health OrganizationCompletedInfluenza A Subtype H5N1 InfectionVietnam
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza A Virus, H5N1 Subtype | Influenza A Virus | Influenzavirus A | H5N1 Virus | OrthomyxovirdaeUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza A Virus, H5N1 Subtype | Influenza A Virus | Influenzavirus A | Orthomyxoviridae | H5N1 VirusUnited States
-
Emory UniversityNational Institute of Allergy and Infectious Diseases (NIAID)CompletedDurability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response (HIPCVAX-010S)Influenza A Subtype H5N1 InfectionUnited States
-
National Institute of Allergy and Infectious Diseases...Emory UniversityCompletedInfluenza A Virus, H5N1 SubtypeUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
SeqirusNovartis VaccinesCompletedInfluenza | Influenza, Human | Influenza A Virus, H5N1 Subtype | Flu, Human | Flu, AvianAustralia, Germany, Italy
-
Biomedical Advanced Research and Development AuthorityCompletedInfluenza A Virus, H5N1 SubtypeUnited States
-
South East Asia Infectious Disease Clinical Research...University of Oxford; Wellcome TrustCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States